German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to ...

In July this year, Genentech submitted a biologic license application to the US Food and Drug Administration (FDA) for the antibody–drug conjugate ... expression to help design our clinical ...

Synaffix’s glycan-based antibody–drug conjugate technology is experiencing ... stage and marketed ADC technologies in head-to-head laboratory studies. Experimental in vivo testing in-house ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

In this video, Robert DeBernardo, MD, shares insight on antibody-drug conjugates as treatment for patients with cancer, a topic discussed at Society of Gynecologic Oncology Annual Meeting on Women’s ...

New facility is expected to serve as a global hub for accelerating the development of next-generation antibody-drug ...

penetration and antibody drug conjugate (ADC) design. The company continues to enroll its HARMONIC trial for LP-300 at sites around the globe with the most recent focus on Taiwan and Japan ...

REVEAL GENOMICS and Ona Therapeutics today announced a strategic collaboration aimed at accelerating the clinical development ...

Roche has secured its third antibody-drug conjugate pact of the year, this time agreeing to hand $36 million in upfront payments to Oxford BioTherapeutics. The agreement will also see U.K.-based ...

An investigational antibody-drug conjugate proved active and safe for ... have a similar type of drug and study design, the ...

They created a modular drug platform that conjugates non-natural peptide inhibitors (NNPIs) with antibodies, creating antibody-peptide ... nature of the APIC design means it can be adapted to ...

The Japanese pharmaceutical company Taiho Pharmaceutical is set to acquire the Swiss antibody-drug conjugate (ADC ... Araris have been collaborating to design new ADC drugs since late 2023 ...